IART241220P35000
- 10.43
- 0.000.00%
Integra Lifesciences Newsroom
Morgan Stanley Initiates Integra Lifesciences(IART.US) With Sell Rating, Announces Target Price $20
Integra LifeSciences Assumed With an Underweight at Morgan Stanley
Reasons to Retain IART Stock in Your Portfolio for Now
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
Integra's DuraSeal Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research
J.P. Morgan Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $24
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Maintains Target Price $26
Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Raises Target Price to $26
Integra LifeSciences Price Target Raised to $26 From $21 at Truist
Integra LifeSciences Is Maintained at Sell by Citigroup
Integra Lifesciences Analyst Ratings
Morgan Stanley Remains a Sell on Integra Lifesciences (IART)
Express News | Integra Lifesciences Holdings Corp : Citigroup Raises Target Price to $22 From $16
Earnings Call: Integra LifeSciences Reports Q3 Revenue Decline, New CEO
JMP Securities Maintains Integra Lifesciences(IART.US) With Buy Rating, Maintains Target Price $35
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Integra Lifesciences (IART)
Q3 2024 Integra Lifesciences Holdings Corp Earnings Call
Integra LifeSciences Announces Q3 2024 Financial Results
Integra LifeSciences Holdings Corporation (IART) Q3 2024 Earnings Call Transcript Summary
Integra Lifesciences | 10-Q: Q3 2024 Earnings Report